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ABSTRACT 
Gut-associated lymphoid tissues (GALT) are enriched in CCR6+ Th17-polarized CD4+ T-
cells that contribute to HIV-1 persistence during antiretroviral therapy (ART). This raises 
the need for Th17-targeted immunotherapies. In an effort to identify mechanisms 
governing HIV-1 permissiveness/persistence in gut-homing Th17 cells, we analyzed the 
transcriptome of CCR6+ versus CCR6- T-cells exposed to the gut-homing inducer 
retinoic acid (RA) and performed functional validations in colon biopsies of HIV-
infected individuals receiving ART (HIV+ART). Although both CCR6+ and CCR6- T-
cells acquired gut-homing markers upon RA exposure, the modulation of unique sets of 
genes coincided with preferential HIV-1 replication in RA-treated CCR6+ T-cells. This 
molecular signature included the up-regulation of HIV-dependency factors acting at 
entry/post-entry levels, such as CCR5 and PI3K-Akt-mTORC1 signaling pathway. Of 
note, mTOR expression/phosphorylation was distinctively induced by RA in CCR6+ T-
cells. Consistently, mTOR inhibitors counteracted the effect of RA on HIV replication in 
vitro and viral reactivation in CD4+ T-cells from HIV+ART individuals, via post-entry 
mechanisms independent of CCR5. Finally, CCR6+ versus CCR6- T-cells infiltrating the 
colon of HIV+ART individuals expressed unique molecular signature including higher 
levels of CCR5, integrin β7, and mTOR phosphorylation. Together, our results identify 
mTOR as a druggable key regulator of HIV permissiveness in gut-homing CCR6+ T-
cells.  
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INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) causes the progressive depletion 
of CD4+ T-cells thus impairing the ability of the immune system to fight pathogens. 
Although current antiretroviral therapies (ART) efficiently control viral replication and 
restore CD4 counts, the HIV eradication is not achieved (1-3). Major CD4+ T-cell 
alterations occur in gut-associated lymphoid tissues (GALT) rapidly upon HIV 
transmission (4, 5) and these alterations persist despite viral suppressive ART (3, 6), even 
in patients treated during acute HIV infection (7). The GALT is considered an important 
site of HIV replication and viral reservoir persistence during ART (8). GALT-infiltrating 
CD4+ T-cells  represent optimal HIV targets likely due to their high expression of CCR5 
(4, 5, 8), a major co-receptor for HIV entry (9-11), and integrin α4β7, a gut-homing 
molecule (12) identified as an HIV-binding molecule (13). Very recently, integrin α4β7 
blocking Abs proved efficacy in controlling viral replication upon ART interruption in a 
SIV infection model (14), indicative that interfering with HIV replication in gut-homing 
α4β7+CD4+ T-cells represents a potential curative strategy.  
 
Among GALT-infiltrating CD4+ T-cells, Th17 cells play a beneficial role in 
maintaining epithelial cell integrity at barrier surfaces via the production of effector 
cytokines under the control of  lineage-specific transcription factors (15). Studies by our 
group and others demonstrated that Th17-polarized CCR6+CD4+ T-cells are highly 
permissive to infection (16-18), as a consequence of their expression of HIV dependency 
factors (HDFs) acting at entry and post-entry levels (19, 20), combined with the lack of 
HIV restriction mechanisms (21-23). Most recently, CD4+ T-cells expressing the Th17 
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markers CCR6/RORγt were identified as the first targets of SIV during vaginal 
transmission (24); also, the detrimental role of viral permissive CCR6+ T-cell infiltration 
into the gut was documented (25). The depletion of Th17 cells from the GALT upon HIV 
infection persists despite viral-suppressive ART (26-28), even when ART is intensified 
with integrase and CCR5 inhibitors (29). Other promising strategies tested for mucosal 
Th17 restoration include an ideal ART initiation at very early stages of infection (Fiebig 
I/II but not III) (7), the use of probiotics, and IL-21 supplementation (30-32). The non-
restoration of GALT Th17 cells leads to significant damages of the intestinal barrier thus 
allowing the microbial translocation, a cause for chronic immune activation and 
occurrence of non-AIDS co-morbidities during ART (3, 6, 33). Despite their dramatic 
depletion, long-lived Th17 cells contribute to HIV reservoir persistence during ART (34, 
35). Consistently, our group identified a subset of CCR6+CCR4-CXCR3- Th17 cells 
predominant in blood and lymph nodes and carrying replication-competent HIV 
reservoirs (36) and further demonstrated preferential HIV-DNA persistence in colon 
infiltrating CCR6+CD4+ T-cells during ART (37). These advances orient our search for 
immunotherapeutic strategies to limit HIV infection/persistence in mucosal Th17 cells in 
the ART era. 
 
The homing of CCR6+ Th17 cells into the GALT is mediated via the 
CCR6/CCL20 axis (28, 38), as well as the adhesion molecule integrin α4β7 (12) and 
chemokine receptor CCR9 (39). The imprinting for gut-homing  is induced by all-trans 
retinoic acid (ATRA) (40), a vitamin A metabolite produced by GALT dendritic cells 
(41). Our previous studies demonstrated that ATRA increases HIV-1 permissiveness 
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preferentially in CCR6+ compared to CCR6- T-cells (42). This effect coincided with the 
preferential ability of ATRA to up-regulate the expression of the HIV co-receptor CCR5 
on CCR6+ T-cells, indicative of a most efficient HIV entry. Nevertheless, exposure to 
single-round VSV-G-pseudotyped HIV entering cells by endocytosis provided evidence 
that ATRA also promotes HIV replication in gut-homing CCR6+ T-cells via post-entry 
mechanisms (42). These findings led to the current hypothesis that CCR6 is a marker for 
Th17-polarized CD4+ T-cells transcriptionally programmed to become HIV targets in the 
gut, where ATRA promotes the expression of unidentified HIV permissiveness factors, 
which may be manipulated to protect gut-homing Th17 cells from HIV. 
 
In our search for new druggable molecular targets to prevent HIV 
replication/persistence in gut-homing Th17 cells, herein we performed a genome-wide 
transcriptional profiling to identify HDFs modulated by ATRA in memory CCR6+ T-
cells. Together, our studies i) provide an in-depth characterization of molecular 
mechanisms contributing to HIV replication/persistence in ATRA-exposed CCR6+ Th17 
cells; ii) identified mTOR as a druggable target modulated by ATRA in these cells; and 
iii) support the beneficial use of mTOR inhibitors in clinics to preserve mucosal Th17 
cells from HIV infection/persistence during ART.  
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RESULTS 
Transmitted/founder (T/F) HIV preferentially infects retinoic-acid treated 
CCR6+CD4+ T-cells. We previously reported that all-trans retinoic acid (ATRA) 
mediated-imprinting for gut-homing increases replication of the laboratory-adapted R5 
NL4.3BaL HIV preferentially in CCR6+ versus CCR6- T-cells (42). T/F HIV strains are 
isolated early upon seroconversion and are unique in their virulence/sensitivity to 
antiviral mechanisms (43). To determine whether T/F HIV also target gut-homing CCR6+ 
T-cells for preferential replication, FACS-sorted memory CCR6+ and CCR6- T-cells 
stimulated via CD3/CD28 in the presence/absence of ATRA were exposed in parallel to 
T/F THRO (44) and NL4.3BaL HIV (Figure 1A). The relative frequency of CCR6+ and 
CCR6- T-cells in peripheral blood mononuclear cells (PBMCs) before sort is depicted in 
Figure 1B-C. The dose of ATRA used (10 nM) (42) is consistent with physiological 
plasma levels (40) and had no influence on cell viability (data not shown). ATRA 
robustly increases replication of both NL4.3BaL and T/F THRO HIV in CCR6+ T-cells, 
while the effects on CCR6- T-cells were only minor, as reflected by the quantification of 
early (RU5), late (Gag), and integrated (Alu/HIV) HIV reverse transcripts (Figure 1 D-
E). Thus, T/F similar to NL4.3BaL HIV also target ATRA-treated CCR6+ T-cells for 
preferential replication, suggesting a critical role played by gut-homing CCR6+ T-cells 
during the early steps of mucosal HIV transmission. 
 
CCR6+ versus CCR6- T-cells exhibit higher proliferation, TNF-α production, and 
NF-κB DNA-binding activity in the presence/absence of ATRA. In search of post-
entry permissiveness mechanisms, we first investigated whether ATRA modulated 
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proliferation and IL-2 production. In the absence of ATRA, CCR6+ compared to CCR6- 
T-cells exhibited higher proliferation upon TCR triggering but a markedly lower 
production of IL-2 (Suppl. Figure 1A-C), consistent with previous studies (16), likely as a 
consequence of RORγt-mediated IL-2 inhibition (45). ATRA further decreased IL-2 
production in CCR6+ T-cells but had no significant effect on cell proliferation (Suppl. 
Figure 1A-C). Levels of CD25 (IL-2Rα) were similarly high on CCR6+ and CCR6- T-
cells exposed or not to ATRA (Suppl. Figure 1D-G), indicative that differences in IL-2 
production are not related to IL-2 auto-consumption. Thus, increased HIV replication in 
CCR6+ T-cells upon exposure to ATRA cannot be explained by enhanced cell 
proliferation and/or IL-2 production.  
 
HIV permissiveness in CCR6+Th17 versus CCR6-Th1 cells is associated with higher NF-
κB nuclear translocation (20). The pro-inflammatory cytokine TNF-α enhances HIV 
replication, in part by triggering the NF-κB pathway (46). This prompted us to 
investigate differences in TNF-α production and NF-κB-p65 activity. Upon TCR 
triggering, CCR6+ versus CCR6- T-cells produced significantly higher levels of TNF-α in 
the absence of ATRA; although ATRA slightly decreased TNF-α production in CCR6+ 
T-cells, levels remained significantly higher in ATRA-treated CCR6+ versus CCR6- T-
cells (Suppl. Figure 2A). The NF-κB-p65 DNA-binding activity was higher in CCR6+ 
versus CCR6- T-cell nuclei when cells were cultured in the presence/absence of ATRA; 
exposure to ATRA slightly decreased NF-κB-p65 DNA-binding activity in CCR6+ T-
cells (Suppl. Figure 2B), consistent with previous reports (47). Nevertheless, NF-κB-p65 
DNA-binding activity remained significantly higher in ATRA-treated CCR6+ versus 
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CCR6- T-cells (Suppl. Figure 2B). Together these results demonstrate that TNF-α 
production and NF-κB-p65 nuclear translocation/DNA-binding activity are significantly 
higher in memory CCR6+ versus CCR6- T-cells upon TCR triggering, but ATRA has no 
positive impact on these differences.  
 
ATRA promotes a unique transcriptional program associated with HIV 
permissiveness in CCR6+ T-cells. To gain insights into mechanisms underlying the 
differential effects of ATRA on CCR6+ versus CCR6- T-cells, their ability to integrate 
ATRA-mediated signals was investigated. CCR6+ and CCR6- T-cells expressed similar 
levels of RA receptor alpha (RARα) mRNA ex vivo (Figure 2A) and ATRA up-regulated 
the expression of RA-inducible gene I (RIG-I)/Retinoic acid receptor responder protein 3 
(RARRES3), a direct target of RA (48), in both cell subsets (Figure 2B). We 
hypothesized that CCR6+ and CCR6- T-cell subsets respond to ATRA in distinct 
fashions, with the expression of HIV dependency factors (HDFs) being promoted 
preferentially in CCR6+ T-cells. To test this hypothesis, a genome-wide transcriptional 
profiling was performed in CCR6+ and CCR6- T-cells stimulated via the TCR in the 
presence/absence of ATRA for four days; this time point coincided with the time of HIV 
exposure in Figure 1. 
 
Differentially expressed genes were identified based on p-values (p) or adjusted p-values 
(adj. p) and fold change (FC) of gene expression. Results in Figure 2C and Suppl. Tables 
1-4 illustrate transcriptional differences between CCR6+ and CCR6- T-cells upon TCR 
triggering in the presence/absence of ATRA. In the absence of ATRA, up-regulated 
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transcripts (n=348; adj. p-values<0.05, FC cut-off 1.3) in CCR6+ versus CCR6- T-cells 
included Th17 markers such as CCL20, IL-22, IL-17F, CTSH, KLRB1/CD161, IL-8, 
RORA, CSF2/GM-CSF, IL-26, RORC, CCR6, SGK1, PPARG, IL-23R, ARNTL, and 
PTPN13 (Suppl. Table 1). Transcripts up-regulated by ATRA in CCR6+ T-cells (n=95; 
adj. p-values<0.05, FC cut-off 1.3) included RARRES3, CD38, DHRS3, UBD, LGMN, 
EVI5, LZTFL1, NAPSA, GBP4, HIC1, CCR9, CCR2, CXCR6, and ITGB7 (Suppl. 
Table 2). Transcripts up-regulated by ATRA in CCR6- T-cells (n=119; adj. p-
values<0.05, FC cut-off 1.3) included NAPSA, CD38, EVI5, SAMD9, GALR2, DHRS3, 
ANKRD37, PTGER2, SLC26A4, and RARRES3, ARG2, APOBEC3B, RIPK2, and 
NFIL3 (Suppl. Table 3). The analysis of the n=319 transcripts over expressed in ATRA-
treated CCR6+ versus CCR6- T-cells revealed the preservation of a Th17 signature (e.g., 
CCL20, IL-17F, CTSH, IL-22, KLRB1, CSF2, ANTXR2, GPR56, CXCR6, KLF2, 
RORC, RORA, S100A4, CCR6, MAP3K4, CD96, IL-26, FURIN, ABCB1, ARNTL, and 
PTPN13) (Suppl. Table 4). Finally, in the presence/absence of ATRA, CCR6+ versus 
CCR6- T-cells show superior expression of the Th17 markers RORC, ARNTL, and 
CCR6, and inferior expression of the RORC nuclear repressor NFIL3 (49) (Suppl. Figure 
3). Together these results demonstrate that CCR6+ and CCR6- T-cells respond to ATRA 
in a unique transcriptional fashion and that ATRA exposure does not modify the Th17-
polarisation profile of CCR6+ T-cells.  
 
An extended intelligent search within top modulated transcripts revealed that ATRA 
induced expression of gut-homing markers integrin α4, integrin β7 and CCR9 (12) in 
both CCR6+ and CCR6- T-cells. Of note, CXCR6, a minor HIV co-receptor (50, 51), was 
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significantly up-regulated by ATRA in CCR6+ but not CCR6- T-cells (Suppl. Tables 2-4; 
Suppl. Figure 3). FACS analysis validated the microarray results for integrin β7 and 
CXCR6 expression (Suppl. Figure 4A-C). Although CCR5 transcripts were not 
differentially expressed in microarrays (data not shown), we confirm (42) that ATRA 
significantly up-regulates CCR5 preferentially on CCR6+ T-cells (Suppl. Figure 4A and 
D). This coincided with the up-regulation of KLF2 (Suppl. Figure 3), a positive regulator 
of CCR5 transcription (52). The down-regulation of CCR5 ligands CCL3 and CCL3L1 
by ATRA was mainly observed in CCR6+ T-cells, indicative of a more efficient CCR5-
mediated HIV entry (53). Although the T-cell activation marker CD38 was similarly up-
regulated by ATRA in both subsets (Suppl. Figure 3), transcripts for MAP3K4, a Th17-
specific kinase (54) we previously identified as a HDF (20), were expressed at superior 
levels and up-regulated by ATRA in CCR6+ versus CCR6- T-cells (Suppl. Figure 3). 
Moreover, the transcripts for PPARγ, a transcriptional repressor of RORγt (55) and Th17-
intrinsec negative regulator of HIV replication (19), was down-regulated by ATRA 
specifically in CCR6+ T-cells (Suppl. Figure 3). Furthermore, CCR6+ versus CCR6- T-
cells stimulated via the TCR in the presence/absence of ATRA expressed decreased 
levels of interferon (IFN) stimulated genes, such as IFITM1, 2, and 3, and IRF8 (Suppl. 
Tables 1-4), consistent with the low Th17 ability to respond to IFN (23). Finally, 
although differences in the expression of SAMHD1, a key IFN-induced HIV restriction 
factor (22, 56, 57), were not observed in the microarrays, in the presence/absence of 
ATRA, levels of SAMHD1 mRNA measured by RT-PCR were significantly lower in 
CCR6+ versus CCR6- T-cells (Suppl. Figure 5). This stresses the existence of false 
negatives in high-throughput transcriptional screenings. Together, these findings reveal 
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multiple HDFs acting at entry and post-entry levels to facilitate HIV replication in 
ATRA-treated CCR6+ T-cells, as well as a state of antiviral immunity acting at different 
levels in CCR6- T-cells. 
 
 Among probe sets differentially modulated by ATRA in CCR6+ and CCR6- T-cells, (p-
value<0.05), only 466 transcripts were shared, while 1,285 and 1,538 transcripts were 
unique to CCR6+ and CCR6- T-cells, respectively (Figure 2D). A meta-analysis using the 
NCBI HIV-1 interactions data-base allowed the identification of human genes previously 
described to enhance HIV-1 protein expression that were differentially regulated by 
ATRA in CCR6+ versus CCR6- T-cells (Suppl. Figure 6). Among those transcripts, 
LGALS3, ADAM15, TRIM8, IL-1α, FOXO3, and ARNTL were up-regulated by ATRA 
in CCR6+ versus CCR6- T-cells (Suppl. Figure 3 and 6).  
 
Finally, Gene Set Variation Analysis (GSVA) identified pathways modulated by ATRA 
in CCR6+ T-cells, including the Akt and PI3K signaling pathways (Figure 3), critical for 
the Th17 polarization (58-60). A custom pathway was created using the genes from 
BIOCARTA_AKT_PATHWAY and PID_PI3K_PLC_TRK_PATHWAY, genes that 
were differentially modulated by ATRA in CCR6+ T-cells (Figure 4A). Of note, the 
mammalian target of rapamycin (mTOR) appeared up-regulated by ATRA in CCR6+ T-
cells in this gene interaction network representation (Figure 4A). Ingenuity Pathway 
Analysis (IPA) was further used to illustrate genes associated with the mTORC1 pathway 
and regulated by ATRA in CCR6+ T-cells (Figure 4B).  
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Together, this genome-wide transcriptional analysis reveals unique molecular signatures 
associated with HIV permissiveness in Th17-polarized CCR6+ T-cells upon exposure to 
ATRA and point to a critical role played by mTOR in this process. 
 
ATRA induces mTOR expression and phosphorylation selectively in CCR6+ T-cells. 
To explore the potential contribution of mTOR to HIV permissiveness in ATRA-treated 
CCR6+ T-cells, the expression of total and phosphorylated mTOR was first investigated 
by western blotting in sorted CCR6+ and CCR6- T-cells stimulated via the TCR in the 
presence/absence of ATRA. Levels of total/phosphorylated mTOR were low to 
undetectable in TCR-activated CCR6+ T-cells but significantly increased by ATRA 
treatment. In contrast, TCR-activated CCR6- T-cells expressed high levels of 
total/phosphorylated mTOR and ATRA did not modify this expression (Figure 5A-B). 
The molecular weight of the main mTOR band was 80 kDa, which corresponds to the β 
isoform of mTOR typically expressed in T-cells (61). To further validate these results, we 
performed semi-quantitative RT-PCR and visualized on gel the expression of mTOR 
mRNA corresponding to isoform β (2,118 Kb), using established primers (61). Levels of 
mTOR isoform β mRNA were significantly higher in CCR6+ T-cells upon exposure to 
ATRA (Suppl. Figure 7). The findings that mTOR mRNA expression and mTOR 
phosphorylation are induced by ATRA preferentially in CCR6+ T-cells point to the 
existence of mTOR-dependent HIV permissiveness mechanisms in gut-homing CCR6+ 
T-cells. 
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mTORC1/2 inhibitors counteract the effect of ATRA on HIV replication. To 
determine the functional role of ATRA-mediated mTOR activity, two commercially 
available mTOR inhibitors were tested for their ability to counteract the effect of ATRA 
on HIV permissiveness: rapamycin, an inhibitor of mTORC1, and INK128, an inhibitor 
of mTORC1/2 (62). Memory CD4+ T-cells were stimulated via the TCR and further 
exposed to HIV in the presence/absence of ATRA, rapamycin or INK128 (Figure 6A). 
Rapamycin and INK128 significantly reduced levels of early/late reverse transcripts and 
integrated HIV-DNA in ATRA-treated T-cells from five different donors, with INK128 
having the most robust inhibitory effects, especially when added before and after 
infection (Figure 6B-D). Similarly, rapamycin and most significantly INK128 had a 
robust inhibitory effect on HIV replication measured by HIV-p24 ELISA at days 3, 6 and 
9 post-infection (Figure 6E). Of note, the treatment with mTOR inhibitors in combination 
with ATRA significantly reduced the ability of cells to produce IL-17A but did not alter 
IFN-γ production, cell viability and proliferation (Suppl. Figure 8A-D). Similar 
experiments were further performed with FACS-sorted memory CCR6+/CCR6- T-cells. 
INK128 significantly reduced HIV integration/replication in ATRA-treated CCR6+ T-
cells. Although levels of HIV integration/replication were lower in CCR6- compared to 
CCR6+ T-cells, INK128 similarly acted on CCR6- T-cells (Figure 7A-B), consistent with 
the mTOR expression in these cells (Figure 5; Suppl. Figure 7). Together, these results 
support the role of ATRA-induced mTOR signaling pathway as a positive regulator of 
HIV permissiveness in gut-homing CCR6+ T-cells. 
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mTORC1/2 inhibitors limit HIV replication at post-entry level in ATRA-treated T-
cells. Studies in humanized mice demonstrated the ability of rapamycin and INK128 to 
inhibit HIV replication via the regulation of CCR5 expression (62). To investigate this 
possibility, we tested the effects of rapamycin and INK128 on CCR5 expression in 
memory CD4+ T-cells stimulated via TCR in the presence/absence of ATRA. Although 
rapamycin and INK128 significantly reduced CCR5 expression in the absence of ATRA, 
no significant changes were observed in the presence of ATRA (Figure 8A-B). Similarly, 
rapamycin and INK128 had no significant effects on the expression of integrin β7 (Figure 
8C-D), a gut-homing molecule induced by ATRA (12) that was also identified as an 
HIV-gp120 binding molecule (13). To further distinguish between HIV entry and post-
entry mTOR-mediated mechanisms in the context of ATRA, we performed a single-
round infection using replication-defective VSV-G-pseudotyped HIV and tested the 
effects of rapamycin or INK128 on HIV reverse transcription and integration. Both 
rapamycin and INK128 induced a partial decrease in levels of early (59±3 and 65±7% 
inhibition) and late (88±2 and 90±5% inhibition) HIV reverse transcript and an almost 
complete abrogation of HIV-DNA integration (98±0.1 and 99±0.1% inhibition, n=3) 
(Figure 8E-G). Together these results demonstrate that mTORC1/2 inhibitors limit HIV 
replication in gut-homing CCR6+CD4+ T-cells via post-entry mechanisms, during reverse 
transcription and prior to integration, without impact on CCR5- and/or integrin β7-
mediated viral entry or cell homing into the gut. 
 
ATRA promotes HIV reactivation in CD4+ T-cells of ART-treated individuals in an 
mTOR-dependent manner. In a very recent study, we demonstrated that ATRA 
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facilitates HIV reactivation from latency in CCR6+CD4+ T-cells from ART-treated 
individuals (37). To determine whether HIV reservoir reactivation was dependent on 
mTOR activity, an optimized viral outgrowth assay (VOA) was performed in the 
presence/absence of ATRA and mTORC1/2 inhibitor INK128 (Figure 9A). Consistent 
with previous findings (37), ATRA significantly improved the efficacy of HIV 
reactivation in memory CD4+ T-cells isolated from ART-treated individuals (Suppl. 
Table 5), as measured by intracellular HIV-p24 staining (Figure 9B-C) and soluble HIV-
p24 in cell-culture supernatants at day 12 post-reactivation (Figure 9D). Of particular 
importance, INK128 inhibited HIV reactivation mediated by TCR triggering in the 
presence of ATRA (Figure 9B-D). Further, we tested the effects of INK128 on HIV 
reservoir reactivation in memory CCR6+ and CCR6- T-cells isolated by FACS from 
ART-treated individuals (Suppl. Table 5). In the absence of ATRA, HIV reactivation was 
observed in CCR6+ but not CCR6- T-cells in 1/3 donors (ART #3), while in the presence 
of ATRA HIV reactivation occurred in 3/3 donors preferentially (ART #3) or only 
(ART#4 and ART #6) in CCR6+ T-cells. Of particular importance, INK128 dramatically 
reduced HIV reactivation in ATRA-treated CCR6+ T-cells, as measured by intracellular 
HIV-p24 expression (Figure 9E-F) and soluble HIV-p24 production in cell-culture 
supernatants at day 12 post-reactivation (data not shown). Together, these results reveal 
mTOR as a key player in ATRA-mediated HIV reactivation in CCR6+ T-cells of ART-
treated individuals. 
 
Colon-infiltrating CCR6+CD4+ T-cells express high levels of CCR5, integrin β7, and 
phosphorylated mTOR. The GALT is enriched in DCs metabolizing vitamin A into 
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ATRA (41). We further explored whether the molecular “signature” induced by ATRA 
in vitro including the up-regulation of CCR5, integrin β7 and mTOR phosphorylation on 
CCR6+ T-cells can be observed as well in the GALT. To test this possibility, we had 
access to matched blood and sigmoid biopsies from n=10 HIV-infected individuals 
receiving ART (Suppl. Table 5; COL #1-10). Memory CD4+ T-cells were identified 
using the gating strategy depicted in Figure 10A and further analyzed for the expression 
of CCR5, integrin β7, and phosphorylated mTOR in CCR6+ versus CCR6- T-cells. The 
expression of CCR5 and integrin β7 was higher on cells from the colon versus the blood; 
with colon-infiltrating CCR6+ versus CCR6- T-cells expressing significantly higher levels 
of CCR5 and integrin β7 (Figure 10B-E). Similarly, mTOR phosphorylation was mainly 
observed in the colon, with colon-infiltrating CCR6+ versus CCR6- T-cells expressing the 
highest levels of phosphorylated mTOR in all individuals tested (Figure 10F-G). Thus, 
the activation of the mTOR pathway occurs almost exclusively in colon-infiltrating 
CCR6+ T-cells and coincides with the highest levels of CCR5 and integrin β7 expression. 
These results provide a molecular explanation for the preferential HIV replication in 
colon CCR6+ T-cells and point to mTOR as a new antiviral drug target in these cells 
(Figure 11).   
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Discussion 
The role of all-trans retinoic acid (ATRA) in regulating tolerance and immunity via the 
modulation of regulatory and effector functions of CD4+ T-cells, respectively, is well-
established (41). Our current results support the idea that in the intestinal environment 
HIV takes advantage of ATRA-mediated signaling pathways for replication/persistence 
in CCR6+CD4+ T-cells. Briefly, we i) identified mTOR as a major regulator of HIV 
permissiveness in CCR6+CD4+ T-cells with gut-homing tropism mimicked in vitro by 
exposure to ATRA; ii) demonstrated the ability of mTOR inhibitors to counteract the 
effects of ATRA on HIV replication in vitro and viral reservoir reactivation in T-cells 
from ART-treated individuals; and iii) revealed that CCR6+CD4+ T-cells infiltrating the 
colon of HIV-infected individuals on ART express a unique signature comprising high 
levels of CCR5, integrin β7, and phosphorylated mTOR, signature likely reflecting 
exposure to ATRA in vivo (Figure 11). Considering the strategic location of Th17 cells at 
portal sites of HIV/SIV entry (6, 24, 27, 28, 63), as well as their important role in 
maintaining mucosal immunity homeostasis in the context of a complex microbiota (6, 
64, 65), our results point to the potential beneficial use of mTOR inhibitors in preventing 
HIV infection/persistence in gut-homing Th17 cells. 
 
In this manuscript, we used the Illumina bead array technology to unveil post-entry HIV 
regulatory mechanisms  modulated by ATRA in CCR6+ versus CCR6- T-cells. Among 
genes commonly modulated by ATRA in CCR6+ and CCR6- T-cells, the RA-inducible 
gene-I (RIG-I) is essential for sensing of viral nucleic acids and promoting antiviral 
immunity (66). HIV is known to subvert RIG-I-mediated antiviral mechanisms (67); this 
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may explain robust HIV replication in RIG-I-expressing ATRA-treated CCR6+ T-cells. 
Of particular importance, Li et al. recently demonstrated that acitretin, a RA derivative, 
increases HIV transcription in CD4+ T-cells from ART-treated HIV-infected individuals 
and enhances RIG-I signaling thus leading to an antiviral response and the apoptosis of 
infected cells (68). Similarly, in a previous report (37) and in this manuscript, we 
demonstrated that ATRA significantly increases HIV reactivation in a viral outgrowth 
assay (VOA) without significant changes observed in T-cell survival/proliferation. 
Differences between our results and those published by Li et al. (68), may be explained 
by differences in the experimental design. Nevertheless, these findings commonly 
support the fact that ATRA promotes HIV reservoir reactivation. 
 
A meta-analysis using the NCBI HIV interaction database revealed HDFs preferentially 
expressed by ATRA-exposed CCR6+ T-cells. These HDFs include LGALS3,  promoting 
HIV-1 budding via association with Alix and Gag p6 (69); ADAM15, involved in the 
nuclear import of the HIV-1 pre-integration complex (70); TRIM8, a regulator of NF-κB 
and STAT3-dependent signaling cascades (20, 71); and ARNTL (72), a component of the 
circadian clock machinery and regulator of Th17 development (49). All these HDFs 
contribute to robust HIV replication in gut-homing CCR6+ T-cells. 
 
Gene Set Variation Analysis (GSVA) of transcripts uniquely modulated by ATRA in 
CCR6+ T-cells identified unique pathways, including Akt and PI3K. The network 
representation of Akt/PI3K pathways,  previously linked to Th17 lineage polarization 
(58-60) and reported to be up-regulated in human lamina propria T-cells (73), pointed to 
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the up-regulation of mTOR, a metabolic sensor involved in the regulation of numerous 
cellular functions via the formation of two different signaling complexes, mTORC1 and 
mTORC2 (74-77). Considering the documented role of mTOR-mediated processes in the 
positive regulation of HIV replication (62, 78), we proceeded to the validation of mTOR 
expression at protein and mRNA levels, as well as functional validations, in cells from 
the blood and/or colon of HIV-infected individuals receiving ART and uninfected study 
participants.  
 
The regulation of HIV permissiveness via mTOR-dependent mechanisms was 
demonstrated by the use of  mTORC1 (rapamycin) and/or mTORC1/2 (INK128) 
inhibitors, that counteracted the effects of ATRA on HIV replication in CCR6+ T-cells in 
vitro and inhibited HIV reservoir reactivation in an ATRA-based VOA performed with 
CCR6+ T-cells from ART-treated individuals. Nevertheless, mTOR 
expression/phosphorylation is not always associated with HIV permissiveness. Indeed, 
CCR6- T-cells are relatively resistant to HIV despite high levels of mTOR expression, 
likely due to the  existence of HIV restriction mechanisms acting at different levels 
including entry (low/undetectable CCR5 expression), reverse transcription (high 
SAMHD1 expression), and/or transcription (limited TNF-α production and NF-κB 
activity). Thus, mTOR favors HIV replication/reactivation only within the unique 
transcriptional context of ATRA-exposed CCR6+ T-cells. 
 
Evidence exists in the literature that mTOR regulates HIV replication via multiple 
mechanisms (78, 79). One possible mechanism is via the regulation of CCR5 expression 
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(62). However, CCR5 expression on ATRA-treated T-cells was not affected by mTOR 
inhibitors. This suggests that ATRA induces CCR5 expression via mTOR-independent 
mechanisms and that mTOR regulation of HIV permissiveness in gut-homing CD4+ T-
cells likely occurs at post-entry levels. Consistent with the evidence that mTOR regulates 
nucleotide biosynthesis essential for transcription (76, 80, 81), mTOR inhibitors may 
limit HIV reverse transcription by reducing the pool of nucleotides. Indeed, our single-
round infection using VSV-G-pseudotyped HIV revealed restriction mechanisms acting 
during reverse transcription and prior to integration. Moreover, mTOR is a well-
established regulator of autophagy (79, 82), a process that may be involved in the 
degradation of the incoming HIV upon fusion/uncoating (83, 84). By promoting the 
mTOR activity, ATRA may impair the autophagy process in CCR5+CCR6+ T-cells at 
mucosal sites. Furthermore, considering the fact that ATRA-treated CCR6+ T-cells 
maintain their Th17 features (42) and that mTORC1 via the induction of the kinase S6K2 
is involved in the nuclear translocation of RORC (60, 85), one other possibility is that 
mTOR inhibitors interfere with the RORC-mediated transcriptional program in Th17 
cells, which is favorable to HIV replication (20). Consistent with this hypothesis, we 
demonstrated that decreased HIV replication in the presence of rapamycin and INK128 
coincided with a significant reduction in IL-17A production by ATRA-treated CD4+ T-
cells.  
 
Of particular importance, we found that CCR6+ but not CCR6- T-cells infiltrating the 
colon of HIV-infected individuals receiving ART express a unique molecular signature 
including superior levels of CCR5, integrin β7 and phosphorylated mTOR expression, 
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likely as a consequence of ATRA exposure in the intestinal environment (12, 41). In line 
with our recent report that HIV-DNA persists in colon-infiltrating CCR6+ T-cells during 
ART (37), it remains to be determined whether mTOR expression identifies a fraction of 
CCR6+ T-cells enriched in HIV-DNA and whether mTOR activation contributes to 
residual HIV replication in colon-infiltrating CCR6+ T-cells during ART.  
 
While this manuscript was in preparation for submission, Besnard et al. reported the 
results of a shRNA screen that revealed mTOR as a regulator of HIV latency (86) via 
mechanisms involving CDK9 and NF-κB activation that controls Tat-dependent HIV 
transcription (86). Also, Martin et al. reported on the potential beneficial use of 
rapamycin in the context of HIV “shock-an-kill” strategies (87). These two reports (86, 
87) further support the conclusions of our current study revealing the key role played by 
mTOR in regulating multiple post-entry and post-integration HIV replication steps in gut-
homing Th17-polarized CCR6+ T-cells.  
 
In conclusion, our findings point to CCR6 as a “zip code” molecule expressed on the 
surface of CD4+ T-cells transcriptionally programmed to become HIV targets upon 
recruitment into the intestine and provide the first detailed molecular explanation for 
preferential HIV/SIV replication and persistence in gut-homing CCR6+CD4+ T-cells (24, 
25, 37, 42). Most significantly, we reveal the role of the mTOR pathway in regulating 
effector functions as well as HIV permissiveness in gut-homing CCR6+ Th17 cells at 
multiple post-entry levels. Additionally, we demonstrate the ability of mTOR inhibitors 
to counteract the effects of ATRA on HIV replication/reactivation in CCR6+ T-cells. Our 
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findings raise new questions on the potential beneficial effects of mTOR inhibitors in 
decreasing HIV reservoirs and restoring the Th17-mediated immunity at the intestinal 
level during ART. This knowledge will open the path for new studies toward the 
implementation of new therapeutic strategies aimed at HIV functional cure.  
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EXPERIMENTAL PROCEDURES 
Study subjects 
Study subjects were recruited at the Montreal Chest Institute, McGill University Health 
Centre, and CHUM-Hôpital Saint-Luc (Montreal, Quebec). PBMCs were collected by 
leukapheresis (88) and cryopreserved until use. Sigmoid biopsies (≈32 biopsies/donor) 
were collected from HIV-infected individuals receiving antiretroviral therapy (ART) 
(Suppl. Table 5) during colonoscopy and processed using Liberase DL (Roche 
Diagnostics), as previously described (37, 89, 90). Matched peripheral blood (20 
ml/donor) was collected the same day from biopsy donors. 
 
Flow cytometry staining 
Surface staining was performed with fluorochrome-conjugated Abs (Suppl. Table 6), as 
previously described (16). Cells extracted from sigmoid biopsies and matched PBMCs 
were stained on the surface with a cocktail of CD3-Alexa700, CD4-PE-Cy7, CD45RA-
APC-eF780, CCR5-FITC, integrin β7-FITC, and CCR6-PE Abs, as well as non-T cell 
lineage Abs: CD326-BV650, CD8-PerCP-Cy5.5, CD19-PerCP-Cy5.5, CD66b-PerCP-
Cy5.5 (37). Intracellular staining was subsequently performed with phosphorylated-
mTOR (S2448)-eFluor-450 Abs (eBiosciences). The viability dye LIVE/DEAD® Fixable 
Aqua Dead Cell Stain Kit (Invitrogen) was used to exclude dead cells. Cells were 
analyzed using a LSRII cytometer, Diva version 6 (BD Biosciences, San Jose, CA), and 
FlowJo version 10.0.6 (Tree Star, Inc). Flow cytometry gates were defined using the 
fluorescence minus one (FMO) strategy (16, 91). 
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Magnetic (MACS) and fluorescence activated cell sorting (FACS) 
Total or memory CD4+ T-cells were enriched from PBMCs by negative selection using 
magnetic beads (MACS, Miltenyi), with a purity >95%, as previously described (42). 
Cells were then stained with CD45RA-APC-Cy7 and CCR6-PE Abs and a cocktail of 
FITC-conjugated Abs to exclude CD8+ T-cells (CD8), NK (CD56), and B cells (CD19). 
The sorting gates were set on FITCneg memory (CD45RAneg) CCR6+/CCR6- T-cells 
that were subsequently sorted by flow cytometry (BDAria III), with dead cells being 
excluded. Post-sort quality control analysis demonstrated >97% CCR6+/CCR6- T-cell 
purity, as previously reported (42). 
 
HIV-1 infection in vitro 
The following HIV-1 molecular clones were used in this study: (i) replication-competent 
CCR5-using (R5) NL4.3BAL; (ii) single-round VSVG-HIV-GFP, an env-deficient NL4.3 
provirus pseudotyped with the VSV-G envelope and encoding for gfp in place of nef (42, 
92); and (iii) replication-competent Transmitted/Founder (T/F) THRO. The full-length 
T/F THRO HIV-1 Infectious Molecular Clone (Cat #11919) was obtained from Dr. John 
Kappes through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (44). 
HIV stocks were produced, titrated, and used to infect cells (25-50 ng HIV-p24/106 cells), 
as previously described (16, 19, 20, 36, 42). 
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Quantification of integrated and Gag HIV-DNA 
Levels of integrated and Gag HIV-DNA were quantified in cell lysates by ultrasensitive 
nested real-time PCR (105 cells/test in triplicates; detection limit, 3 HIV-DNA copies), as 
previously described (16, 19, 20, 36, 37, 42, 93).  
 
Quantification of early HIV reverse transcripts 
Early HIV reverse transcripts (RU5) were quantified using a SYBR™ Green master mix 
(Qiagen). The external primers were: forward AA55 5'-
CGTCTAGAGATTTTCCACAC-3' and reverse M667 5'-
CTAACTAGGGAACCCACTG-3'. The internal primers were: forward SK29 5'-
ACTAGGGAACCCACTGCT-3' and reverse SK30 5'-GGTCTGAGGGATCTCTAG-3' 
(94). The HIV and CD3 DNA were amplified together in the first PCR and separately 
during the second PCR (LightCycler; Roche). The first PCR products (diluted 1/10) were 
used as template for the second PCR: 5 min at 94°C, 35 cycles of 1 min at 94°C, 1 min at 
50°C, and 30 sec at 72°C; and final elongation of 15 min at 72°C. The ACH2 cells 
carrying one copy of integrated HIV DNA per cell (NIH AIDS reagent program) were 
used as a standard curve, as previously described (16, 19, 20, 36, 37, 42, 93).  
 
Genome-wide transcriptional profiling 
Genome-wide transcriptional profiling was performed in collaboration with Génome 
Québec (Montreal, Quebec, Canada) using the Illumina bead array technology, as 
previously described (20). Briefly, total RNA was isolated using the RNeasy kit (Qiagen) 
and quantified using the Pearl nanophotometer (Implen, Germany). The RNA quality was 
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determined using the Agilent 2100 Bioanalyzer chip. High quality RNA was reverse 
transcribed and hybridized on the Illumina HumanHT-12 v4 Expression BeadChip 
providing coverage for more than 47,000 transcripts and known spliced variants across 
the human transcriptome. The expression of differentially expressed genes was analyzed 
as previously described (19, 20, 36). The entire microarray dataset and technical 
information requested by Minimum Information About a Microarray Experiment 
(MIAME) are available at the Gene Expression Omnibus (GEO) database under 
accession number GSE93660. Differentially expressed genes (cut-off 1.3-fold; p <0.05) 
were classified through Gene Ontology using the NetAffx web-based application 
(Affymetrix), while differentially expressed pathways were identified using Ingenuity 
Pathway Analysis (IPA) and Gene Set Variation Analysis (GSVA). Corresponding heat 
maps for biological function categories were generated using programming language R 
(19, 20, 36). 
 
Real-time RT-PCR 
One step SYBR Green real-time RT-PCR (Qiagen) was carried out in a LightCycler 480 
II (Roche) according to manufacturer’s recommendations, as we previously reported (16, 
19, 20, 36, 42). Briefly, a standard curve was prepared with cDNA obtained upon reverse 
transcription of total RNA using specific QuantiTect Primers (Qiagen). The expression of 
each gene was normalized to the internal control 28S rRNA (forward 5′-
CGAGATTCCTGTCCCCACTA-3′; reverse 5′-GGGGCCACCTCCTTATTCTA-3, 
IDT). Melting curve analysis performed after real-time amplification revealed the 
uniformity of thermal dissociation profile for each amplification product. Samples 
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without template or without reverse transcriptase were used as negative controls. Each 
RT-PCR reaction was performed in triplicate. 
 
mTOR protein and mRNA quantification 
Cells were lysed with RIPA buffer 1x (Cell Signaling) containing phosphatase inhibitors 
(PhosSTOP) and protease inhibitors (Complete Mini EDTA-free, Roche), for 10 minutes 
at 4°C and centrifuged at 14,000g for 10 min. Proteins were quantified in supernatants by 
Bradford assay (Biorad). Samples (15 µg protein/well) were loaded onto 7% acrylamide 
gels and SDS-PAGE migration was performed (90 min, 100 V). Proteins were transferred 
to PVDF membranes and further blotted with phosphorylated (D9C2) or total mTOR 
(7C10) Abs (Cell signaling). Proteins were revealed with ECL prime western blotting 
detection reagent (Amersham, GE Healthcare). In parallel, the expression of the mTOR 
mRNA was measured by semi-quantitative RT-PCR performed using the superscript III 
one-step RT-PCR system (Invitrogen, USA) and specific primers (forward:  S1, 
ATGCTTGGAACCGGACCTGCCG ; reverse: AS1, 
TACCAGAAAGGGCACCAGCCAAT) (Integrated DNA Technologies, USA) that 
could amplify both mTOR isoforms α (7.647Kb Kb) and β (2.118 Kb) (61) (Suppl. 
Figure 7A). However, the RT-PCR conditions were set for the optimal amplification of 
the short β mTOR isoform, as follows: reverse transcription (30 min at 55 °C), 40 cycles 
of PCR amplification (denaturation, 15 secs at 94 °C; annealing, 30 secs at 63 °C; 
elongation, 130 secs at 68 °C) and final elongation (15 min at 68 °C). mTOR expression 
was normalized relative to 28S rRNA. Total RNA was extracted using the RNeasy kit 
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(Qiagen) and used for RT-PCR amplification of mTOR (250 ng/test) and 28S rRNA (5 
ng/test).  
 
Nuclear NF-κB quantification 
The NF-κB DNA-binding activity was quantified using an activity-based ELISA kit 
(Assay Designs & Stressgen, Ann Arbor, Mi, USA) according to the manufacturer’s 
protocol, as described (20). Briefly, nuclear extracts were obtained using the BD 
transfactor extraction kit (Clonetech Laboratories). Nuclear protein content was 
quantified by Nanodrop (Thermo Scientific). The active form of NF-κB-p65 was 
quantified in nuclear extracts (1 μg protein/test). The assay used streptavidin-coated 
plates with bound NF-κB biotinylated-consensus sequence to capture only the active 
form of NF-κB. The captured NF-κB was then incubated with a specific NF-κB-p65 Abs 
further detected using an HRP conjugated Abs. The assay was developed with a 
chemiluminescent substrate and the signal was detected using a luminometer. Results 
were expressed as Light Units. The specificity of the binding was demonstrated by the 
use of a wild type and mutated NF-κB Competitor Duplex included in the kit.  
 
ELISA quantification 
HIV-p24 levels were quantified in cell culture supernatants using a homemade ELISA, as 
described (16, 19, 20, 36, 37, 42). Cytokine levels in cell culture supernatants were 
quantified by ELISA assays specific for TNF-α, CCL20 (R&D Systems), IL-17, IFN-γ 
and IL-2 (eBioscience) according to the manufacturers’ protocols. 
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Viral outgrowth assay 
This viral outgrowth assay (VOA) was designed to allow optimal HIV reservoir 
reactivation from small numbers of primary CD4+ T-cells (36, 37). Briefly, memory 
CD4+ T-cells (2x106 cells/ml/well) or FACS sorted memory CCR6+/CCR6- T-cells (106 
cells/ml/well) were cultured in 48-well plates in the presence of immobilized CD3 and 
soluble CD28 Abs (1 µg/ml) for 3 days. Cells were further cultured in the presence of IL-
2 (5 ng/ml) up to day 12. Every 3 days, cells were split and media was refreshed. The 
VOA was performed in the presence/absence of ATRA (10 nM) and/or INK128 (50 nM). 
HIV-p24 levels were quantified by ELISA in cell culture supernatants, while intracellular 
HIV-p24 expression was quantified by flow cytometry at day 12 post-reactivation. 
 
Statistics 
Statistical analyses were performed using the GraphPad Prism 6. RM One-way ANOVA 
or ordinary ANOVA with Tukey’s or Dunnetts’s post-test were used for multiple 
comparisons. Two-tailed paired t-test was used for matched pairwise analyses. A P-value 
less than 0.05 was considered significant. (*, p-value<0.05; **, p-value<0.01; ***p-
value<0.001; ****p-value<0.0001). Details are included in Figure legends. 
 
Microarrays accession number 
The entire microarray dataset and technical information requested by Minimum 
Information About a Microarray Experiment (MIAME) are available at the Gene 
Expression Omnibus database under accession number GSE93660. 
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Study approval 
This study used biological samples (blood and sigmoid biopsies) from HIV-infected and 
uninfected participants and was conducted in compliance with the principles included in 
the Declaration of Helsinki. This study received approval from the Institutional Review 
Board of the McGill University Health Centre and the CHUM-Research Centre, 
Montreal, Quebec, Canada. All human participants provided written informed consent for 
their participation in the study and agreed with the publication of the scientific results.  
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Figure 1: Replication advantage of transmitted founder HIV in CCR6+ versus CCR6- T-cells upon
exposure to ATRA. Memory CCR6+ and CCR6- T-cells were isolated by MACS (magnetic-activated cell
sorting) and FACS from the PBMCs (peripheral blood mononuclear cells) of HIV-uninfected individuals and
tested for their ability to replicate HIV in vitro. Shown is (A) the experimental flow chart, (B) the expression of
CCR6 and CD45RA on total CD4+ T-cells isolated using magnetic beads and on memory (CD45RA-) CCR6+ and
CCR6- T-cells isolated by FACS, and (C) the frequency of CCR6- and CCR6+ T-cells within memory CD4+ T-
cells in n=10 donors. Paired t-Test p-values are indicated on the graphs (D-E). Sorted cells were stimulated via
CD3/CD28 in presence/absence of ATRA (all-trans retinoic acid) (10 nM) for 4 days and exposed to (D)
transmitted founder (T/F) THRO HIV or (E) laboratory-adapted NL4.3BaL HIV (25 ng HIV-p24/106 cells). Early
(RU5 primers) and late (Gag primers) HIV-DNA reverse transcripts, as well as integrated HIV-DNA levels
(Alu/HIV-LTR primers) were quantified by nested real-time PCR in matched subsets isolated from n=2 different
donors at day 3 post-infection (mean±SD of triplicate wells). (D-E) One-way ANOVA p-values with the
significance of the Tukey’s multiple comparisons test are indicated on the figures. Each symbol represents one
triplicate value. Planas et al., Figure 1
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Figure 2: ATRA differentially modulates gene expression in CCR6- and CCR6+ T-cells. Memory
CCR6+/CCR6- T-cells were sorted and stimulated as described in Figure 1. Shown is the SYBR green real-time
RT-PCR quantification of RAR (retinoic acid receptor α) mRNA ex vivo (A; n=2, mean±SD) and RIG-
I/RARRES3 (retinoic acid induced gene I) mRNA upon CD3/CD28 triggering in the presence/absence of ATRA
(B; n=4, mean±SEM). (A-B) Paired t-Test p-values are indicated on the graphs. Each symbol represents (A) one
duplicate value or (B) one different donor. (C-E) Total RNA from matched T-cell subsets of n=6 different HIV-
uninfected donors was used for genome-wide transcriptional profiling. One-way ANOVA analysis identified
differentially expressed genes based on p-values or adjusted p-values (<0.05) and/or fold-change (FC, cut-off
1.3). (C) Shown are volcano plots for all probes in each linear model with the log2 FC on the x axis and the
negative logarithm of the adjusted p-values for false discovery rate (FDR) on the y axis. The red/green color
code is based on the 5% FDR threshold. (D) The Venn diagram depicts the number of probe-sets modulated by
ATRA uniquely in CCR6+ (grey) and CCR6- T-cells (white) (p-values<0.05), as well as 466 probe sets commonly
modulated.
Planas et al., Figure 3
Figure 3: Canonical pathways modulated by ATRA in CCR6+ T-cells. Memory CCR6+/CCR6- T-cells were
sorted and stimulated as described in Figure 1. Total RNA from matched T-cell subsets of n=6 different HIV-
uninfected donors was used for genome-wide transcriptional profiling as described in Figure 2. One-way ANOVA
analysis identified differentially expressed genes based on p-values or adjusted p-values (<0.05) and/or fold-
change (FC, cut-off 1.3). The heat map depicts top 34 pathways up (red) and down (blue) modulated by ATRA in
CCR6+ T-cells, identified using gene-set variation analysis (GSVA; p-value<0.01;enrichment z-score).
Planas et al., Figure 4
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Figure 4: Components of the AKT/PI3K pathways modulated by ATRA in CCR6+ T-cells. Memory
CCR6+/CCR6- T-cells were sorted and stimulated as described in Figure 1. Total RNA from matched T-cell
subsets of n=6 different HIV-uninfected donors was used for genome-wide transcriptional profiling as described
in Figure 2. One-way ANOVA analysis identified differentially expressed genes based on p-values or adjusted p-
values (<0.05) and/or fold-change (FC, cut-off 1.3). Shown are (A) combined BIOCARTA_AKT_PATHWAY and
PID_PI3K_PLC_TRK_PATHWAY Canonical pathways significantly modulated by ATRA in CCR6+ T-cells,
identified using Ingenuity Pathway Analysis; and (B) Gene expression network generated using individual
genes representing REACTOME_MTORC1_MEDIATED_SIGNALING, significantly modulated by ATRA in
CCR6+ T-cells identified through GSVA. The color code is based on expression FC (red and green for up-
regulated and down-regulated transcripts, respectively). Nodes representing individual genes are annotated with
their corresponding p-values and FC.
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Figure 5: ATRA induces mTOR expression and phosphorylation selectively in CCR6+ T-cells. Memory
CCR6+ and CCR6- T-cell subsets were sorted and stimulated as described in Figure 1. (A) Cell lysates were
used to visualize total and phosphorylated mTOR expression by Western Blotting. (B) Levels of total and
phosphorylated mTOR expression were quantified by densitometry and normalized relative to -actin levels. Of
note, the molecular weight of the predominant mTOR band was 80 kDa, corresponding to the β isoform of
mTOR (1). Shown are results obtained with cells from two different donors.
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Figure 6: mTOR inhibitors counteract the effect of ATRA on HIV permissiveness in memory CD4+ T-
cells. The ability of mTOR inhibitors to counteract the effects of ATRA on HIV replication was tested in total
memory CD4+ T-cells (A). Briefly, total memory CD4+ T-cells were stimulated via CD3/CD28 in
presence/absence of ATRA and/or rapamycin (10 nM) or INK128 (50 nM) for 4 days. Then, cells were exposed
to replication competent T/F HIV THRO (25 ng HIV-p24/106 cells). Further, cells were cultured for 9 additional
days in presence/absence of ATRA and/or rapamycin or INK128. Shown are the relative RU5, Gag, and
integrated HIV-DNA levels quantified by real-time nested PCR at day 3 post-infection (with the range of absolute
HIV-DNA copies/106 cells in ATRA-treated cells, considered 100%, being indicated on the figures) (B-D) and
HIV-p24 levels quantified by ELISA in cell culture supernatants at days, 3, 6 and 9 post-infection (E) (n=5,
mean±SEM) . The RM one-way ANOVA p-values (B-E), with the significance of the Dunnetts’s (relative to cells
stimulated via the TCR in the presence of ATRA) (B-C-D) or Tukey’s (E) multiple comparisons test are indicated
on the figures. Each symbol represents one different donor.
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Figure 7: mTOR inhibitors counteract the effect of ATRA on HIV permissiveness in sorted CCR6+ and
CCR6- T-cells. Memory CCR6+ and CCR6- T-cells were sorted as depicted in Figure 1 and stimulated via
CD3/CD28 in presence of ATRA or ATRA and INK128 (50 nM) for 4 days. Then, cells were exposed to
replication competent T/F HIV THRO (25 ng HIV-p24/106 cells). Further, cells were cultured for 9 additional days
in presence of ATRA or ATRA and INK128. (A-B) Shown are absolute levels of integrated HIV-DNA at day 3
post-infection (A) and HIV-p24 levels in cell culture supernatants at day 6 post-infection (B) (n=3, mean±SD of
triplicate wells), Ordinary one-way ANOVA with the significance of the Tukey’s multiple comparisons test are
indicated on the figures. Each symbol represents one experimental triplicate value in individual donors.
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Figure 8: mTOR inhibitors limit HIV replication at post-entry levels in ATRA-treated CD4+ T-cells. (A-D)
Memory CD4+ T-cells were first analyzed for the surface expression of CCR5 and integrin β7 at day 4 post-TCR
triggering in the presence/absence of ATRA (10 nM), rapamycin (10nM), and/or INK128 (50nM). Shown are
levels of CCR5 (A) and integrin β7 (C) expression in one representative donor and statistical analysis of CCR5
(B; n=3) and integrin β7 (D; n=5) expression in different donors (meanSEM). (E-G) Then, stimulated cells were
exposed to VSV-G-pseudotyped HIV (25 ng HIV-p24/106 cells) (single round infection) and cultured in
presence/absence of ATRA and/or rapamycin or INK128 for 3 additional days. Levels of RU5 (E), Gag (F) and
integrated HIV-DNA (G) were quantified by nested real-time PCR in cells harvested at day 3 post-infection. (E-
G) Shown are relative HIV-DNA levels (meanSEM; n=3); the range of absolute HIV-DNA copies/106 cells in
ATRA-treated CCR6+ T-cells (considered 100%) is indicated on the figure. The RM one-way ANOVA p-values
with the significance of the Tukey’s (B-D) or Dunnetts’s (relative to cells stimulated via the TCR the presence of
ATRA) (E, F, G) multiple comparisons tests are indicated on the graphs. Each symbol represents one different
donor.
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Planas et al., Figure 6 continued
Figure 9: Drug-mediated mTOR blockade counteracts the enhancing effects of ATRA on HIV reactivation
in a viral outgrowth assay. HIV reactivation was measured in a viral outgrowth assay (VOA), as summarized in
the flowchart (A). Briefly, total memory CD4+ T-cells (B-D; n=5) and FACS-sorted memory CCR6+ and CCR6-
T-cells (E-F; n=3) were isolated from PBMCs of HIV+ART individuals (Table S5; ART#1-6). Cells were activated
via CD3/CD28 and cultured in presence/absence of ATRA (10 nM) and/or INK128 (50 nM). Shown is
intracellular HIV-p24 expression in total memory CD4+ T-cells (B-C) and sorted memory CCR6+ and CCR6- T-
cells (E-F) quantified by FACS, as well as HIV-p24 levels quantified by ELISA in cell culture supernatants of total
memory CD4+ T-cells (D) harvested at day 12 post-activation. Results are depicted in individual donors. Each
point represents one experimental triplicate (mean±SD of triplicate wells). The RM one-way ANOVA p-values
with the significance of the Dunnetts’s multiple comparisons test (relative to cells stimulated via the TCR the
presence of ATRA) (C-D) and the ordinary one-way ANOVA with the significance of the Tukey’s multiple
comparisons test (F) are indicated in the figures.
Planas et al., Figure 10
Figure 10: Memory CCR6+CD4+ T-cells infiltrating the colon of HIV+ART individuals express high levels
of CCR5, integrin β7, and phosphorylated mTOR. Matched blood and sigmoid biopsies were collected from
HIV-infected individuals with undetectable plasma viral load (<40 HIV-RNA copies/ml) under ART (Table S5;
COL#1-10). Cells were extracted and stained with a cocktail of specific Abs. Shown is the gating strategy for the
flow cytometry identification of CD3+CD4+CD45RA- T-cells (A), as well as the surface expression of CCR5 (B-C)
and integrin β7 (D-E) and the intracellular expression of phosphorylated mTOR (F-G) on CCR6+ and CCR6-
subsets from sigmoid biopsies versus PBMC in one representative donor (B, D, and F) and statistical analysis in
all donors (C, E, and G). Paired t-Test values are indicated on the graphs.
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Figure 11: Mechanisms contributing to HIV replication in gut-homing CCR6+ T-cells. In this manuscript, we
provide evidence that CCR6 is a marker for memory CD4+ T-cells programmed to become HIV targets,
especially in the intestinal environment rich in retinoic acid, due to their expression of a unique Th17-polarized
transcriptional program and a mTOR-governed metabolic state. We propose the use of mTOR inhibitors together
with ART to protect gut-homing Th17 cells from HIV infection/persistence.
